October 12-13, 2023
Hilton Meadowlands · East Rutherford, NJ
Drug development efforts in the rare disease space have continually expanded and evolved over the past few decades. Contributing factors include increased public awareness, encouraging drug regulation changes, scientific advancement in cellular/molecular biology and genetics, development of innovative trial designs, large influx of capital investment, availability of scientific talent through decades of cultivation, etc.
As a result, a great number of regulators, academicians, and industry statisticians now work to bring these orphan drugs to patients, facing unique technical issues and challenges. However, at least in the US, there is no statistical conference dedicated to such unique issues and challenges. Given the large unmet need, the New England Statistical Society (NESS) provides this unique conference so that statisticians across the entire rare disease drug development spectrum have a common “home” to exchange ideas and share experiences, and also to network. The first conference took place in 2018 at Biogen in Cambridge, Massachusetts. Since then, the workshop has been held at Seaport Hotel Boston, as virtual webinar and at University Connecticut, Storrs campus. It has been a one-day workshop with detailed presentations and discussions.
In 2023, we will be hosting a fully in-person two-day workshop (Oct 12-13, 2023) at Hilton Meadowlands, New York Metropolitan Area. This year's workshop theme is: Accelerating Rare Disease Drug Development through Novel Endpoint, RWE and Innovation. We are looking forward to seeing you at the conference.
|June 30th, 2023||Conference registration opens|
|August 15th, 2023||Early registration ends|
|October 2nd, 2023||Registration closes|